3OX7
 
 | | The crystal structure of uPA complex with peptide inhibitor MH027 at pH4.6 | | Descriptor: | MH027, SULFATE ION, TETRAETHYLENE GLYCOL, ... | | Authors: | Jiang, L.G, Andreasen, P.A, Huang, M.D. | | Deposit date: | 2010-09-21 | | Release date: | 2011-08-10 | | Last modified: | 2023-11-01 | | Method: | X-RAY DIFFRACTION (1.58 Å) | | Cite: | The binding mechanism of a peptidic cyclic serine protease inhibitor
J.Mol.Biol., 412, 2011
|
|
3OY6
 | |
3OY5
 | |
3MWI
 | | The complex crystal Structure of Urokianse and 5-nitro-1H-indole-2-amidine | | Descriptor: | 5-nitro-1H-indole-2-carboximidamide, SULFATE ION, Urokinase-type plasminogen activator | | Authors: | Jiang, L.G, Yu, H.Y, Yuan, C, Huang, Z.X, Huang, M.D. | | Deposit date: | 2010-05-06 | | Release date: | 2011-06-01 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (2.03 Å) | | Cite: | The complex crystal Structure of Urokianse and 5-nitro-1H-indole-2-amidine
To be Published
|
|
7DZD
 | |
5YC6
 | | The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH4.6 | | Descriptor: | 1-(4-BROMOPHENYL)METHANAMINE, SULFATE ION, TRIETHYLENE GLYCOL, ... | | Authors: | Jiang, L.G, Zhang, X, Huang, M.D. | | Deposit date: | 2017-09-06 | | Release date: | 2018-10-03 | | Last modified: | 2024-11-06 | | Method: | X-RAY DIFFRACTION (1.18 Å) | | Cite: | Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases
Rsc Adv, 8, 2018
|
|
5YC7
 | |
5Z1C
 | | The crystal structure of uPA in complex with 4-Iodobenzylamine at pH7.4 | | Descriptor: | 1-(4-iodophenyl)methanamine, Urokinase-type plasminogen activator | | Authors: | Jiang, L.G, Zhang, X, Luo, Z.P, Huang, M.D. | | Deposit date: | 2017-12-25 | | Release date: | 2018-12-26 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (1.45 Å) | | Cite: | Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases
Rsc Adv, 49, 2018
|
|
5YUP
 | | Crystal Structure of the Fab fragment of FVIIa antibody mAb4F5 | | Descriptor: | the heavy chain of the Fab fragment of FVIIa antibody mAb4F5, the light chain of the Fab fragment of FVIIa antibody mAb4F5 | | Authors: | Jiang, L.G, Persson, E, Huang, M.D. | | Deposit date: | 2017-11-22 | | Release date: | 2019-06-19 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (1.81 Å) | | Cite: | Crystal structure, epitope, and functional impact of an antibody against a superactive FVIIa provide insights into allosteric mechanism.
Res Pract Thromb Haemost, 3, 2019
|
|
6L05
 | | Crystal structure of uPA_H99Y in complex with 50F | | Descriptor: | 3-azanyl-5-(azepan-1-yl)-6-(1-benzofuran-2-yl)-Ncarbamimidoyl-pyrazine-2-carboxamide, Urokinase-type plasminogen activator | | Authors: | Buckley, B, Jiang, L.G, Huang, M.D, Kelso, M, Ranson, M. | | Deposit date: | 2019-09-26 | | Release date: | 2020-09-30 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (2.49 Å) | | Cite: | Crystal structure of uPA_H99Y in complex with 50F
To Be Published
|
|
6L04
 | | Crystal structure of uPA_H99Y in complex with 31F | | Descriptor: | 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide, Urokinase-type plasminogen activator | | Authors: | Buckley, B, Jiang, L.G, Huang, M.D, Kelso, M, Ranson, M. | | Deposit date: | 2019-09-26 | | Release date: | 2020-09-30 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (2.21 Å) | | Cite: | Crystal structure of uPA_H99Y in complex with 31F
To Be Published
|
|
3G7N
 | | Crystal Structure of a Triacylglycerol Lipase from Penicillium Expansum at 1.3 | | Descriptor: | DI(HYDROXYETHYL)ETHER, Lipase, PENTAETHYLENE GLYCOL, ... | | Authors: | Bian, C.B, Yuan, C, Chen, L.Q, Edward, J.M, Lin, L, Jiang, L.G, Huang, Z.X, Huang, M.D. | | Deposit date: | 2009-02-10 | | Release date: | 2010-02-23 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (1.3 Å) | | Cite: | Crystal structure of a triacylglycerol lipase from Penicillium expansum at 1.3 A determined by sulfur SAD
Proteins, 78, 2010
|
|
6JYP
 | | Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide | | Descriptor: | 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide, SULFATE ION, Urokinase-type plasminogen activator | | Authors: | Buckley, B, Jiang, L.G, Huang, M.D, Kelso, M, Ranson, M. | | Deposit date: | 2019-04-27 | | Release date: | 2020-05-13 | | Last modified: | 2024-10-09 | | Method: | X-RAY DIFFRACTION (2.25 Å) | | Cite: | uPA-HMA
To Be Published
|
|
6JYQ
 | | Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide | | Descriptor: | 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide, SULFATE ION, Urokinase-type plasminogen activator | | Authors: | Buckley, B, Jiang, L.G, Huang, M.D, Kelso, M, Ranson, M. | | Deposit date: | 2019-04-27 | | Release date: | 2020-05-13 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (1.75 Å) | | Cite: | H99Y-6F-HMA-pH7
To Be Published
|
|
6AG7
 | | The crystal structure of uPA in complex with HMA-55F | | Descriptor: | 3,5-diamino-N-carbamimidoyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxamide, Urokinase-type plasminogen activator | | Authors: | Buckley, B, Jiang, L.G, Majed, H, Huang, M.D, Kelso, M, Ranson, M. | | Deposit date: | 2018-08-09 | | Release date: | 2019-08-14 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | uPA-HMA
To Be Published
|
|
6AG3
 | | Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide | | Descriptor: | 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide, Urokinase-type plasminogen activator | | Authors: | Buckley, B, Jiang, L.G, Majed, H, Huang, M.D, Kelso, M, Ranson, M. | | Deposit date: | 2018-08-09 | | Release date: | 2019-09-18 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (2.48 Å) | | Cite: | uPA-HMA
To Be Published
|
|
6AG9
 | | Crystal structure of uPA in complex with 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2- carboxamide | | Descriptor: | 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2-carboxamide, SULFATE ION, Urokinase-type plasminogen activator | | Authors: | Buckley, B, Jiang, L.G, Majed, H, Huang, M.D, Kelso, M, Ranson, M. | | Deposit date: | 2018-08-09 | | Release date: | 2019-09-18 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (1.63 Å) | | Cite: | uPA-HMA
To Be Published
|
|
6AG2
 | | uPA-HMA | | Descriptor: | 3,5-bis(azanyl)-N-carbamimidoyl-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxamide, SULFATE ION, Urokinase-type plasminogen activator | | Authors: | Buckley, B, Jiang, L.G, Huang, M.D, Kelso, M, Ranson, M. | | Deposit date: | 2018-08-09 | | Release date: | 2019-09-18 | | Method: | X-RAY DIFFRACTION (1.77 Å) | | Cite: | uPA-HMA
To Be Published
|
|
7WOK
 | | Crystal structure of HSA soaked with cisplatin for one week | | Descriptor: | Albumin, Cisplatin, PHOSPHATE ION | | Authors: | Chen, S.L, Yuan, C, Jiang, L.G, Luo, Z.P, Huang, M.D. | | Deposit date: | 2022-01-21 | | Release date: | 2022-07-20 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Crystallographic analysis of interaction between cisplatin and human serum albumin: Effect of fatty acid.
Int.J.Biol.Macromol., 216, 2022
|
|
7WOJ
 | | Crystal structure of HSA-Myr complex soaked with cisplatin for one week | | Descriptor: | Albumin, Cisplatin, MYRISTIC ACID | | Authors: | Chen, S.L, Yuan, C, Jiang, L.G, Luo, Z.P, Huang, M.D. | | Deposit date: | 2022-01-21 | | Release date: | 2022-07-20 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.89 Å) | | Cite: | Crystallographic analysis of interaction between cisplatin and human serum albumin: Effect of fatty acid.
Int.J.Biol.Macromol., 216, 2022
|
|
5ZC5
 | | uPA-NU-09F | | Descriptor: | 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(4-fluoranyl-1-benzofuran-2-yl)pyrazine-2-carboxamide, Urokinase-type plasminogen activator chain B | | Authors: | Jiang, L.G, Buckley, B.J, Huang, M.D, Kelso, M.J, Ranson, M. | | Deposit date: | 2018-02-15 | | Release date: | 2018-12-19 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
J. Med. Chem., 61, 2018
|
|
7VM4
 | | Crystal structure of uPA in complex with nafamostat | | Descriptor: | 4-carbamimidamidobenzoic acid, TRIETHYLENE GLYCOL, Urokinase-type plasminogen activator | | Authors: | Jiang, L.G, Huang, M.D. | | Deposit date: | 2021-10-07 | | Release date: | 2022-10-12 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (2.01 Å) | | Cite: | Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat.
Biophys.J., 121, 2022
|
|
7VM5
 | |
7VM7
 | | Crystal structure of inactive uPA in complex with nafamostat | | Descriptor: | (6-carbamimidoylnaphthalen-2-yl) 4-carbamimidamidobenzoate, Urokinase-type plasminogen activator chain B | | Authors: | Jiang, L.G, Huang, M.D. | | Deposit date: | 2021-10-07 | | Release date: | 2022-11-23 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (1.87 Å) | | Cite: | Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat.
Biophys.J., 121, 2022
|
|
7VM6
 | | Crystal structure of uPA in complex with 6-amidino-2-naphthol | | Descriptor: | 6-oxidanylnaphthalene-2-carboximidamide, SULFATE ION, TRIETHYLENE GLYCOL, ... | | Authors: | Jiang, L.G, Huang, M.D. | | Deposit date: | 2021-10-07 | | Release date: | 2022-10-12 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (1.79 Å) | | Cite: | Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat.
Biophys.J., 121, 2022
|
|
